Skip to main content
Erschienen in: Pediatric Drugs 3/2009

01.06.2009 | Review Article

Current Pharmacological Management of Gastro-Esophageal Reflux in Children

An Evidence-Based Systematic Review

verfasst von: Mark P. Tighe, Nadeem A. Afzal, Amanda Bevan, Dr R. Mark Beattie

Erschienen in: Pediatric Drugs | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Gastro-esophageal reflux (GER) is a common phenomenon, characterized by the regurgitation of the gastric contents into the esophagus. Gastro-esophageal reflux disease (GERD) is the term applied when GER is associated with sequelae or faltering growth.
The main aims of treatment are to alleviate symptoms, promote normal growth, and prevent complications. Medical treatments for children include (i) altering the viscosity of the feeds with alginates; (ii) altering the gastric pH with antacids, histamine H2 receptor antagonists, and proton pump inhibitors; and (iii) altering the motility of the gut with prokinetics, such as metoclopramide and domperidone.
Our aim was to systematically review the evidence base for the medical treatment of gastro-oesophageal reflux in children. We searched PubMed, AdisOnline, MEDLINE, and EMBASE, and then manually searched reviews from the past 5 years using the key words ‘gastro-esophageal’ (or ‘gastroesophageal’), ‘reflux’, ‘esophagitis’, and ‘child$’ (or ‘infant’) and ‘drug$’ or ‘therapy’. Articles included were in English and had an abstract. We used the levels of evidence adopted by the Centre for Evidence-Based Medicine in Oxford to assess the studies for all reported outcomes that were meaningful to clinicians making decisions about treatment. This included the impact of clinical symptoms, pH study profile, and esophageal appearance at endoscopy.
Five hundred and eight articles were reviewed, of which 56 papers were original, relevant clinical trials. These were assessed further. Many of the studies considered had significant methodological flaws, although based on available evidence the following statements can be made. For infant GERD, ranitidine and omeprazole and probably lansoprazole are safe and effective medications, which promote symptomatic relief, and endoscopic and histological healing of esophagitis. Gaviscon® Infant sachets are safe and can improve symptoms of reflux. There is less evidence to support the use of domperidone or metoclopramide. More evidence is needed before other anti-reflux medications can be recommended. For older children, acid suppression is the mainstay of treatment. The largest evidence base supports the early use of H2 receptor antagonists or proton pump inhibitors.
Literatur
1.
Zurück zum Zitat Tighe MP, Cullen M, Beattie RM. How to use: a pH study. Arch Dis Child Ed Pract Feb 2009; 94: 18–23CrossRef Tighe MP, Cullen M, Beattie RM. How to use: a pH study. Arch Dis Child Ed Pract Feb 2009; 94: 18–23CrossRef
2.
Zurück zum Zitat North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. Paediatric gastro-esophageal reflux clinical practice guidelines. J Pediatr Gastroenterol Nutr 2001; 32Suppl. 2: S1–31 North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. Paediatric gastro-esophageal reflux clinical practice guidelines. J Pediatr Gastroenterol Nutr 2001; 32Suppl. 2: S1–31
3.
Zurück zum Zitat Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastrooesophageal reflux during infancy: a paediatric practice-based survey. Arch Pediatr Adolesc Med 1997; 151: 569–72PubMedCrossRef Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastrooesophageal reflux during infancy: a paediatric practice-based survey. Arch Pediatr Adolesc Med 1997; 151: 569–72PubMedCrossRef
4.
Zurück zum Zitat Martin AJ, Pratt N, Kennedy JD, et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002; 109: 1061–7PubMedCrossRef Martin AJ, Pratt N, Kennedy JD, et al. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002; 109: 1061–7PubMedCrossRef
5.
Zurück zum Zitat Carre IJ. The natural history of partial thoracic stomach (hiatus hernia) in children. Arch Dis Child 1959; 34: 344–53PubMedCrossRef Carre IJ. The natural history of partial thoracic stomach (hiatus hernia) in children. Arch Dis Child 1959; 34: 344–53PubMedCrossRef
6.
Zurück zum Zitat Shepherd RW, Wren J, Evans S, et al. Gastroesophageal reflux in children: clinical profile, course and outcome with active therapy in 126 cases. Clin Pediatr (Phila) 1987; 26: 55–60CrossRef Shepherd RW, Wren J, Evans S, et al. Gastroesophageal reflux in children: clinical profile, course and outcome with active therapy in 126 cases. Clin Pediatr (Phila) 1987; 26: 55–60CrossRef
7.
Zurück zum Zitat Hyams JS, Ricci Jr A, Leichtner AM. Clinical and laboratory correlates of esophagitis in young children. J Pediatr Gastroenterol Nutr 1988; 7: 52–6PubMedCrossRef Hyams JS, Ricci Jr A, Leichtner AM. Clinical and laboratory correlates of esophagitis in young children. J Pediatr Gastroenterol Nutr 1988; 7: 52–6PubMedCrossRef
8.
Zurück zum Zitat Salvatore S, Hauser B, Salvatoni A, et al. Oral ranitidine and duration of gastric pH <4.0 in infants with persisting reflux symptoms. Acta Paediatr 2006; 95(2): 176–81PubMedCrossRef Salvatore S, Hauser B, Salvatoni A, et al. Oral ranitidine and duration of gastric pH <4.0 in infants with persisting reflux symptoms. Acta Paediatr 2006; 95(2): 176–81PubMedCrossRef
9.
Zurück zum Zitat Aggett PJ, Agostoni C, Goulet O, et al. Antireflux or antiregurgitation milk products for infants and young children: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2002 May; 34(5): 496–8PubMedCrossRef Aggett PJ, Agostoni C, Goulet O, et al. Antireflux or antiregurgitation milk products for infants and young children: a commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2002 May; 34(5): 496–8PubMedCrossRef
10.
Zurück zum Zitat Thomson M, Fritscher-Ravens A, Hall S, et al. Endoluminal gastroplication in children with significant gastro-oesophageal reflux disease. Gut 2004 Dec; 53(12): 1745–50PubMedCrossRef Thomson M, Fritscher-Ravens A, Hall S, et al. Endoluminal gastroplication in children with significant gastro-oesophageal reflux disease. Gut 2004 Dec; 53(12): 1745–50PubMedCrossRef
11.
Zurück zum Zitat Hassall E. Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child 2005 Oct; 90(10): 1047–52PubMedCrossRef Hassall E. Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child 2005 Oct; 90(10): 1047–52PubMedCrossRef
13.
Zurück zum Zitat Mandel KG, Daggy BP, Brodie DA. Review article alginate-raft formulations in the treatment of heartburn and acid reflux. Alimen Pharmacol Ther 2000; 14: 669–90CrossRef Mandel KG, Daggy BP, Brodie DA. Review article alginate-raft formulations in the treatment of heartburn and acid reflux. Alimen Pharmacol Ther 2000; 14: 669–90CrossRef
14.
Zurück zum Zitat Gaviscon product information. Hull: Reckitt Benckiser Healthcare (UK) Limited, 2009. (Data on file) Gaviscon product information. Hull: Reckitt Benckiser Healthcare (UK) Limited, 2009. (Data on file)
15.
Zurück zum Zitat Keady S. Update on drugs for gastro-oesophageal reflux disease. Arch Dis Childhood Educ Pract 2007; 92: ep114–8CrossRef Keady S. Update on drugs for gastro-oesophageal reflux disease. Arch Dis Childhood Educ Pract 2007; 92: ep114–8CrossRef
16.
Zurück zum Zitat Joint publication of the British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British national formulary for children. Section 1.1.2. London: BMJ Group, 2007: 53 Joint publication of the British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British national formulary for children. Section 1.1.2. London: BMJ Group, 2007: 53
17.
Zurück zum Zitat Miller S. Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastrooesophageal reflux. Curr Med Res Opin 1999; 15(3): 160–8PubMedCrossRef Miller S. Comparison of the efficacy and safety of a new aluminum-free paediatric alginate preparation and placebo in infants with recurrent gastrooesophageal reflux. Curr Med Res Opin 1999; 15(3): 160–8PubMedCrossRef
18.
Zurück zum Zitat Carroccio A, Iacono G, Montalto F, et al. Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scand J Gastroenterol 1994; 29: 300–4PubMedCrossRef Carroccio A, Iacono G, Montalto F, et al. Domperidone plus magnesium hydroxide and aluminium hydroxide: a valid therapy in children with gastroesophageal reflux. Scand J Gastroenterol 1994; 29: 300–4PubMedCrossRef
19.
Zurück zum Zitat Del Buono R, Wenzl TG, Ball G, et al. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Arch Dis Child 2005 May; 90: 460–3PubMedCrossRef Del Buono R, Wenzl TG, Ball G, et al. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Arch Dis Child 2005 May; 90: 460–3PubMedCrossRef
20.
Zurück zum Zitat Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24h continuous pH monitoring in infants and children. Eur J Pediatr 1987 Mar; 146(2): 156–8PubMedCrossRef Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24h continuous pH monitoring in infants and children. Eur J Pediatr 1987 Mar; 146(2): 156–8PubMedCrossRef
21.
Zurück zum Zitat Forbes D, Hodgson M, Hill R. The effects of Gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr 1986 Jul–Aug; 5(4): 556–9PubMedCrossRef Forbes D, Hodgson M, Hill R. The effects of Gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr 1986 Jul–Aug; 5(4): 556–9PubMedCrossRef
22.
Zurück zum Zitat Greally P, Hampton FJ, MacFadyen UM, et al. Gaviscon and carobel compared with cisapride in gastro-oesophageal reflux. Arch Dis Child 1992; 67: 618–21PubMedCrossRef Greally P, Hampton FJ, MacFadyen UM, et al. Gaviscon and carobel compared with cisapride in gastro-oesophageal reflux. Arch Dis Child 1992; 67: 618–21PubMedCrossRef
23.
Zurück zum Zitat Joint publication ofthe British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British national formulary for children. Section 1.1.1. London: BMJ Group, 2007: 51 Joint publication ofthe British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British national formulary for children. Section 1.1.1. London: BMJ Group, 2007: 51
24.
Zurück zum Zitat Cucchiara S, Staiano A, Romaniello G, et al. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1984; 59: 842–7PubMedCrossRef Cucchiara S, Staiano A, Romaniello G, et al. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1984; 59: 842–7PubMedCrossRef
25.
Zurück zum Zitat Cucchiara S, Franco MT, Terrin G, et al. Role of drug therapy in the treatment of gastro-oesophageal reflux disorder in children. Paediatr Drugs 2000 Jul–Aug; 2(4): 263–72PubMedCrossRef Cucchiara S, Franco MT, Terrin G, et al. Role of drug therapy in the treatment of gastro-oesophageal reflux disorder in children. Paediatr Drugs 2000 Jul–Aug; 2(4): 263–72PubMedCrossRef
26.
Zurück zum Zitat Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolescent Med 1995 Mar; 149: 267–71CrossRef Karjoo M, Kane R. Omeprazole treatment of children with peptic esophagitis refractory to ranitidine therapy. Arch Pediatr Adolescent Med 1995 Mar; 149: 267–71CrossRef
27.
Zurück zum Zitat Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69: 655–9PubMedCrossRef Cucchiara S, Minella R, Iervolino C, et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69: 655–9PubMedCrossRef
28.
Zurück zum Zitat Cucchiara S, Gobio-Casali L, Balli F, et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentre study. J Ped Gastroenterol Nutr 1989; 8: 150–6CrossRef Cucchiara S, Gobio-Casali L, Balli F, et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentre study. J Ped Gastroenterol Nutr 1989; 8: 150–6CrossRef
29.
Zurück zum Zitat Lambert J, Mobassaleh M, Grand RJ. Efficacy of cimetidine for gastric acid suppression in pediatric patients. J Pediatr 1992; 120: 474–8PubMedCrossRef Lambert J, Mobassaleh M, Grand RJ. Efficacy of cimetidine for gastric acid suppression in pediatric patients. J Pediatr 1992; 120: 474–8PubMedCrossRef
30.
Zurück zum Zitat Argüelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med 1989 Jun 9; 86(6A): 73–6PubMedCrossRef Argüelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med 1989 Jun 9; 86(6A): 73–6PubMedCrossRef
31.
Zurück zum Zitat Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003; 17: 1097–107PubMedCrossRef Orenstein SR, Shalaby TM, Devandry SN, et al. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003; 17: 1097–107PubMedCrossRef
32.
Zurück zum Zitat Champion G, Richter JE, Vaezi MF, et al. Duodenogastric reflux: relationship to pH and importance to Barrett’s oesophagus. Gastroenterology 1994; 107: 747–54PubMedCrossRef Champion G, Richter JE, Vaezi MF, et al. Duodenogastric reflux: relationship to pH and importance to Barrett’s oesophagus. Gastroenterology 1994; 107: 747–54PubMedCrossRef
33.
Zurück zum Zitat Israel DM, Hassall E. Omeprazole and other proton pump inhibitors: pharmacology, efficacy and safety with special reference to use in children. J Pediatr Gastroenterol Nutr 1998; 27: 566–79CrossRef Israel DM, Hassall E. Omeprazole and other proton pump inhibitors: pharmacology, efficacy and safety with special reference to use in children. J Pediatr Gastroenterol Nutr 1998; 27: 566–79CrossRef
34.
Zurück zum Zitat Peghini P, Katz P, Bedassy A, et al. Nocturnal acid breakthrough during twice daily (bid) administration of proton pump inhibitor (PPI) [abstract]. Gastroenterology 1997; 112: A255 Peghini P, Katz P, Bedassy A, et al. Nocturnal acid breakthrough during twice daily (bid) administration of proton pump inhibitor (PPI) [abstract]. Gastroenterology 1997; 112: A255
35.
Zurück zum Zitat Joint publication of the British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British national formulary for children. Section 1.3.5. London: BMJ Group, 2007: 63 Joint publication of the British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British national formulary for children. Section 1.3.5. London: BMJ Group, 2007: 63
36.
Zurück zum Zitat Messaouik D, Sautou-Miranda V, Bagel-Boithias S, et al. Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube. Int J Pharm 2005 Aug 11; 299(1–2): 65–72PubMedCrossRef Messaouik D, Sautou-Miranda V, Bagel-Boithias S, et al. Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube. Int J Pharm 2005 Aug 11; 299(1–2): 65–72PubMedCrossRef
37.
Zurück zum Zitat Nelis GF. Ranitidine in the management of gastro-oesophageal reflux disease. Neth J Med 1985; 28(5): 197–200PubMed Nelis GF. Ranitidine in the management of gastro-oesophageal reflux disease. Neth J Med 1985; 28(5): 197–200PubMed
38.
Zurück zum Zitat Joint publication of the British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British national formulary for children. Section 1.3.5. London: BMJ Group, 2007: 62 Joint publication of the British Medical Association, the Royal Pharmaceutical Society of Great Britain, the Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group. British national formulary for children. Section 1.3.5. London: BMJ Group, 2007: 62
39.
Zurück zum Zitat El-Matary W, Dalzell M. Omeprazole-induced hepatitis. Pediatr Emerg Care 2005 Aug; 21(8): 529–30PubMedCrossRef El-Matary W, Dalzell M. Omeprazole-induced hepatitis. Pediatr Emerg Care 2005 Aug; 21(8): 529–30PubMedCrossRef
40.
Zurück zum Zitat Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharm Ther 2002 May; 71(5): 359–67CrossRef Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharm Ther 2002 May; 71(5): 359–67CrossRef
41.
Zurück zum Zitat Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54: 473–500PubMedCrossRef Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54: 473–500PubMedCrossRef
43.
Zurück zum Zitat Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy safety, tolerability and dose requirements. J Pediatr 2000; 137(6): 800–7PubMedCrossRef Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy safety, tolerability and dose requirements. J Pediatr 2000; 137(6): 800–7PubMedCrossRef
44.
Zurück zum Zitat Martin PB, Imong SM, Krischer J, et al. The use of omeprazole for resistant oesophagitis in children. Eur J Ped Surg 1996; 4: 195–7CrossRef Martin PB, Imong SM, Krischer J, et al. The use of omeprazole for resistant oesophagitis in children. Eur J Ped Surg 1996; 4: 195–7CrossRef
45.
Zurück zum Zitat Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1994 Feb; 124(2): 332–4 Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1994 Feb; 124(2): 332–4
46.
Zurück zum Zitat Kato S, Ebina K, Fuji K, et al. Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and 24 hour intragastric activity. J Pediatr 1996; 128(3): 415–21PubMedCrossRef Kato S, Ebina K, Fuji K, et al. Effect of omeprazole in the treatment of refractory acid-related diseases in childhood: endoscopic healing and 24 hour intragastric activity. J Pediatr 1996; 128(3): 415–21PubMedCrossRef
47.
Zurück zum Zitat Alliet P, Raes M, Bruneel E, et al. Omeprazole in infants with cimetidine-resistant peptic esophagitis. J Pediatr 1998; 132(2): 352–4PubMedCrossRef Alliet P, Raes M, Bruneel E, et al. Omeprazole in infants with cimetidine-resistant peptic esophagitis. J Pediatr 1998; 132(2): 352–4PubMedCrossRef
48.
Zurück zum Zitat De Giacomo C, Bawa P, Franceschi M, et al. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997; 24(5): 528–32PubMedCrossRef De Giacomo C, Bawa P, Franceschi M, et al. Omeprazole for severe reflux esophagitis in children. J Pediatr Gastroenterol Nutr 1997; 24(5): 528–32PubMedCrossRef
49.
Zurück zum Zitat Franco MT, Salvin G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000; 32: 600–6CrossRef Franco MT, Salvin G, Terrin G, et al. Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. Dig Liver Dis 2000; 32: 600–6CrossRef
50.
Zurück zum Zitat Fiedorek S, Tolia V, Gold B, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastro-oesophageal reflux disease. J Ped Gastroenterol Nutr 2005; 40(5): 319–27CrossRef Fiedorek S, Tolia V, Gold B, et al. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastro-oesophageal reflux disease. J Ped Gastroenterol Nutr 2005; 40(5): 319–27CrossRef
51.
Zurück zum Zitat Tolia V, Bishop P, Tsou V, et al. Multicenter randomised double blind study comparing 10, 20 and mg pantoprazole in children 5–11years with symptomatic gastroesophageal reflux disease. J Ped Gastroenterol Nutr 2006; 42(4): 384–91CrossRef Tolia V, Bishop P, Tsou V, et al. Multicenter randomised double blind study comparing 10, 20 and mg pantoprazole in children 5–11years with symptomatic gastroesophageal reflux disease. J Ped Gastroenterol Nutr 2006; 42(4): 384–91CrossRef
52.
Zurück zum Zitat Tsou VM, Baker R, Book L, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). 326 Study Group. Clin Pediatr (Phila) 2006 Oct; 45(8): 741–9CrossRef Tsou VM, Baker R, Book L, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). 326 Study Group. Clin Pediatr (Phila) 2006 Oct; 45(8): 741–9CrossRef
53.
Zurück zum Zitat Gold BD, Gunasekaran T, Tolia V, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007 Nov; 45(5): 520–9PubMedCrossRef Gold BD, Gunasekaran T, Tolia V, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007 Nov; 45(5): 520–9PubMedCrossRef
54.
Zurück zum Zitat Terrin BN, McWilliams NB, Maurer HM. Side-effects of metoclopramide as an antiemetic in childhood cancer-chemotherapy. J Pediatr 1984; 104: 183–40 Terrin BN, McWilliams NB, Maurer HM. Side-effects of metoclopramide as an antiemetic in childhood cancer-chemotherapy. J Pediatr 1984; 104: 183–40
55.
Zurück zum Zitat Hyams JS, Zamett LO, Walters JK. Effect of metoclopramide on prolonged intraesophageal pH testing in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1986; 5: 716–20PubMedCrossRef Hyams JS, Zamett LO, Walters JK. Effect of metoclopramide on prolonged intraesophageal pH testing in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr 1986; 5: 716–20PubMedCrossRef
56.
Zurück zum Zitat Tolia V, Calhoun J, Kuhns L, et al. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. J Pediatr 1989; 115(1): 141–5PubMedCrossRef Tolia V, Calhoun J, Kuhns L, et al. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. J Pediatr 1989; 115(1): 141–5PubMedCrossRef
57.
Zurück zum Zitat Pons G, Duhamel JF, Guillot M, et al. Dose-response study of metoclopramide in gastroesophageal reflux in infancy. Fundam Clin Pharmacol 1993; 7(3–4): 161–6PubMedCrossRef Pons G, Duhamel JF, Guillot M, et al. Dose-response study of metoclopramide in gastroesophageal reflux in infancy. Fundam Clin Pharmacol 1993; 7(3–4): 161–6PubMedCrossRef
58.
Zurück zum Zitat De Loore I, Van Ravenstein H. Ameryckx L. Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation: a comparison with metoclopramide. Postgrad Med J 1979; 55: 40–2PubMed De Loore I, Van Ravenstein H. Ameryckx L. Domperidone drops in the symptomatic treatment of chronic paediatric vomiting and regurgitation: a comparison with metoclopramide. Postgrad Med J 1979; 55: 40–2PubMed
59.
Zurück zum Zitat Leung A, Lai P. Use ofmetoclopramide for the treatment of gastrooesophageal reflux in infants and children. Curr Ther Res 1984; 36(5): 911–5 Leung A, Lai P. Use ofmetoclopramide for the treatment of gastrooesophageal reflux in infants and children. Curr Ther Res 1984; 36(5): 911–5
60.
Zurück zum Zitat Craig WR, Hanlon-Dearman A, Sinclair C, et al. Metoclopramide, thickened feeding and positioning for gastro-oesophageal reflux in children under 2 years. Cochrane Database Syst Rev 2004; (3): CD003502 Craig WR, Hanlon-Dearman A, Sinclair C, et al. Metoclopramide, thickened feeding and positioning for gastro-oesophageal reflux in children under 2 years. Cochrane Database Syst Rev 2004; (3): CD003502
61.
Zurück zum Zitat Hibbs AM, Lorch SH. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006; 118: 746–52PubMedCrossRef Hibbs AM, Lorch SH. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006; 118: 746–52PubMedCrossRef
62.
Zurück zum Zitat Shafrir Y, Levy Y, Ben-Amitai D, et al. Oculogyric crisis due to domperidone therapy [case report]. Helv Paediatr Acta 1985; 40(95): 85 Shafrir Y, Levy Y, Ben-Amitai D, et al. Oculogyric crisis due to domperidone therapy [case report]. Helv Paediatr Acta 1985; 40(95): 85
63.
Zurück zum Zitat Franckx J, Noel P. Acute extrapyramidal dysfunction after domperidone administration. Helv Paediatr Acta 1984; 39: 285–8PubMed Franckx J, Noel P. Acute extrapyramidal dysfunction after domperidone administration. Helv Paediatr Acta 1984; 39: 285–8PubMed
64.
Zurück zum Zitat Bines J, Quinlan JE, Treves S, et al. Efficacy of domperidone in infants and children with gastro-oesophageal reflux. J Pediatr Gastroenterol Nutr 1992; 14: 400–5PubMedCrossRef Bines J, Quinlan JE, Treves S, et al. Efficacy of domperidone in infants and children with gastro-oesophageal reflux. J Pediatr Gastroenterol Nutr 1992; 14: 400–5PubMedCrossRef
65.
Zurück zum Zitat Clara R. Chronic regurgitation and vomiting treated with domperidone: a multicenter evaluation. Acta Paediatric Belg 1979; 32: 203–7 Clara R. Chronic regurgitation and vomiting treated with domperidone: a multicenter evaluation. Acta Paediatric Belg 1979; 32: 203–7
66.
Zurück zum Zitat Grill BB, Hillemeier C, Semeraro LA, et al. Effects of domperidone therapy on symptoms and upper gastrointestinal motility in infants with gastro-oesophageal reflux. J Pediatr 1985; 106(2): 311–6PubMedCrossRef Grill BB, Hillemeier C, Semeraro LA, et al. Effects of domperidone therapy on symptoms and upper gastrointestinal motility in infants with gastro-oesophageal reflux. J Pediatr 1985; 106(2): 311–6PubMedCrossRef
67.
Zurück zum Zitat Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005; 59(6): 725–9PubMedCrossRef Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005; 59(6): 725–9PubMedCrossRef
68.
Zurück zum Zitat Vandenplas Y. A proposition for the diagnosis and treatment of gastro-oesophageal reflux in children: a report from ESPGHAN. Eur J Pediatr 1993; 152: 704–11PubMedCrossRef Vandenplas Y. A proposition for the diagnosis and treatment of gastro-oesophageal reflux in children: a report from ESPGHAN. Eur J Pediatr 1993; 152: 704–11PubMedCrossRef
69.
Zurück zum Zitat Committee on Safety of Medicines and Medicines Control Agency. Cisapride (Prepulsid) withdrawn. Curr Prob Pharmacovigil 2000; 26: 9–14 Committee on Safety of Medicines and Medicines Control Agency. Cisapride (Prepulsid) withdrawn. Curr Prob Pharmacovigil 2000; 26: 9–14
70.
Zurück zum Zitat Vandenplas Y, Belli DC, Benatar A, et al. The role of cisapride in the treatment of pediatric gastroesophageal reflux. J Paediatr Gastroenterol Nutr 1999; 28: 518–28CrossRef Vandenplas Y, Belli DC, Benatar A, et al. The role of cisapride in the treatment of pediatric gastroesophageal reflux. J Paediatr Gastroenterol Nutr 1999; 28: 518–28CrossRef
71.
Zurück zum Zitat Vandenplas Y. Reflux esophagitis in infants and children: a report from the working group on gastro-oesophageal reflux disease of the European Society of Paediatric Gastroenterology Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 1994; 18: 413–22PubMedCrossRef Vandenplas Y. Reflux esophagitis in infants and children: a report from the working group on gastro-oesophageal reflux disease of the European Society of Paediatric Gastroenterology Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 1994; 18: 413–22PubMedCrossRef
72.
Zurück zum Zitat Augood C, MacLennon S, Gilbert R, et al. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2003; (4): CD002300PubMed Augood C, MacLennon S, Gilbert R, et al. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev 2003; (4): CD002300PubMed
73.
Zurück zum Zitat Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 1886–99PubMed Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 1886–99PubMed
74.
Zurück zum Zitat Chicella MF, Batres LA, Heesters MF, et al. Prokinetic drug therapy in children: a review of current options. Annals Pharmacother 2005; 39(4): 706–11CrossRef Chicella MF, Batres LA, Heesters MF, et al. Prokinetic drug therapy in children: a review of current options. Annals Pharmacother 2005; 39(4): 706–11CrossRef
75.
Zurück zum Zitat Janssens J, Peters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N EngI J Med 1990; 322: 10218–31CrossRef Janssens J, Peters TL, Vantrappen G, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N EngI J Med 1990; 322: 10218–31CrossRef
76.
Zurück zum Zitat Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 1999; 354: 2101–5PubMedCrossRef Honein MA, Paulozzi LJ, Himelright IM, et al. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 1999; 354: 2101–5PubMedCrossRef
77.
Zurück zum Zitat Orenstein SR, Lofton SW, Orenstein DM, et al. Bethanechol for pediatric gastroesophageal reflux: a prospective blind controlled study. J Pediatr Gastroenterol Nutr 1986; 5: 549–55PubMedCrossRef Orenstein SR, Lofton SW, Orenstein DM, et al. Bethanechol for pediatric gastroesophageal reflux: a prospective blind controlled study. J Pediatr Gastroenterol Nutr 1986; 5: 549–55PubMedCrossRef
78.
Zurück zum Zitat Levi P, Marmo F, Saluzzo C, et al. Bethanechol versus antiacids in the treatment of gastroesophageal reflux. Helv Paediatr Acta 1985 Dec; 40(5): 349–59PubMed Levi P, Marmo F, Saluzzo C, et al. Bethanechol versus antiacids in the treatment of gastroesophageal reflux. Helv Paediatr Acta 1985 Dec; 40(5): 349–59PubMed
79.
Zurück zum Zitat Brodgen RN, Heel RC, Speight TM, et al. Sucralfate: a review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease. Drugs 1984; 27: 194–209CrossRef Brodgen RN, Heel RC, Speight TM, et al. Sucralfate: a review of its pharmacodynamic properties and therapeutic use in peptic ulcer disease. Drugs 1984; 27: 194–209CrossRef
80.
Zurück zum Zitat Herbst JJ. Gastro-oesophageal reflux and gastric emptying. J Pediatr Gastroenterol Nutr 1983; 2Suppl. 1: 335–8CrossRef Herbst JJ. Gastro-oesophageal reflux and gastric emptying. J Pediatr Gastroenterol Nutr 1983; 2Suppl. 1: 335–8CrossRef
81.
Zurück zum Zitat Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; (2): CD003244PubMed Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007; (2): CD003244PubMed
82.
Zurück zum Zitat Gold BD, Freston JW. Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment. Pediatr Drugs 2002; 4(10): 673–85 Gold BD, Freston JW. Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment. Pediatr Drugs 2002; 4(10): 673–85
83.
Zurück zum Zitat Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Pediatr Drugs 2003; 5(1): 25–40 Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Pediatr Drugs 2003; 5(1): 25–40
84.
Zurück zum Zitat Vandenplas Y, Salvatore S, Hauser B. The diagnosis and management of gastro-oesophageal reflux in infants. Early Human Dev 2005; 81: 1011–24CrossRef Vandenplas Y, Salvatore S, Hauser B. The diagnosis and management of gastro-oesophageal reflux in infants. Early Human Dev 2005; 81: 1011–24CrossRef
85.
86.
Zurück zum Zitat Croom KF, Scott LJ. Lansoprazole in the treatment of gastro-oesophageal reflux disease in children and adolescents. Drugs 2005; 65(15): 2129–35PubMedCrossRef Croom KF, Scott LJ. Lansoprazole in the treatment of gastro-oesophageal reflux disease in children and adolescents. Drugs 2005; 65(15): 2129–35PubMedCrossRef
Metadaten
Titel
Current Pharmacological Management of Gastro-Esophageal Reflux in Children
An Evidence-Based Systematic Review
verfasst von
Mark P. Tighe
Nadeem A. Afzal
Amanda Bevan
Dr R. Mark Beattie
Publikationsdatum
01.06.2009
Verlag
Springer International Publishing
Erschienen in
Pediatric Drugs / Ausgabe 3/2009
Print ISSN: 1174-5878
Elektronische ISSN: 1179-2019
DOI
https://doi.org/10.2165/00148581-200911030-00004

Weitere Artikel der Ausgabe 3/2009

Pediatric Drugs 3/2009 Zur Ausgabe

Adis Drug Evaluation

Atomoxetine

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.